MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome rather than the nuclear genome, first described as a regulator of metabolic signaling in mouse studies and later followed into exercise physiology, aging and a first-in-human development program. The amounts, species and adverse-event language below are reported the way the underlying studies describe them, not as guidance for use.
| Fact | Reported value | Source |
|---|---|---|
| Peptide length and origin | 16 amino acids, encoded within the mitochondrial 12S rRNA region rather than a nuclear gene | See what-is-mots-c |
| Primary metabolic endpoints studied in mice | Fasting glucose, insulin sensitivity, body composition (fat mass versus lean mass) | Discussed across the mouse studies in the table below |
| Site of action proposed by the nuclear-translocation study | Nuclear gene expression under metabolic stress, in addition to cytosolic activity | Discussed below, mouse and cell model |
| Exercise-induced circulating change studied in humans | Change in circulating MOTS-c levels measured around an acute exercise session | Discussed below, human study |
| First-in-human synthetic analog program | Early-phase safety and tolerability study of a MOTS-c-derived synthetic peptide, developed under the designation CB4211 | Discussed in the adverse-events section below |
What amounts and routes have been reported in the MOTS-c mouse and primate literature?
The foundational mouse work on MOTS-c established it as a peptide that moves between the cytosol, the nucleus and the plasma membrane depending on metabolic stress, with downstream effects on fasting glucose and body composition. Later work extended the species range and added a human exercise data set. The amounts below are reported exactly as each source states them; none of this is a quantity intended for human use.
| Study | Model and n | Amount and route (as reported) | Endpoint | Finding |
|---|---|---|---|---|
| Foundational mouse metabolic study (mitochondrial-derived peptide, original description) | Mouse, diet-induced obesity and aging cohorts | Synthetic MOTS-c, systemic administration across a multi-week study window; the amount scaled to body weight in the original report | Fasting glucose, insulin sensitivity (glucose tolerance testing), body composition | Treated mice showed improved glucose tolerance and resistance to diet-induced increases in fat mass relative to vehicle-treated mice |
| Nuclear translocation study | Mouse and cultured cell model, metabolic stress conditions (glucose restriction, oxidative stress) | MOTS-c exposure applied directly to cultured cells, with corresponding systemic administration in the mouse arm of the same study | Nuclear localization of the peptide, expression of antioxidant-response genes | Metabolic stress drove the peptide into the nucleus, where it regulated expression of a set of stress-response genes distinct from its cytosolic signaling role |
| Exercise-induced circulating peptide study | Human study cohort plus a mouse arm examining muscle and age-related physical decline | Endogenous MOTS-c measured in blood after an acute bout of exercise; the mouse arm used systemic administration rather than relying on endogenous levels alone | Circulating peptide concentration, muscle function and age-related physical performance measures | Exercise raised circulating MOTS-c, and administration in the aged mouse arm was associated with improved measures of muscle function relative to untreated aged controls |
| Skeletal muscle signaling study | Mouse, muscle wasting and myostatin-signaling model | Systemic MOTS-c administration across a defined study window | Myostatin pathway activity, muscle mass preservation | Treated mice showed reduced myostatin-pathway signaling and relative preservation of muscle mass compared with untreated mice in the same wasting model |
| Preclinical safety package supporting the first-in-human program | Standard preclinical toxicology species used ahead of a first-in-human study, including a non-rodent (primate) arm as is typical for this stage of development | Not a single reported efficacy dose; this stage reports safety margins and exposure rather than a metabolic-endpoint amount | General toxicology, exposure (pharmacokinetic) parameters, tolerated dose range ahead of human exposure | The preclinical package supported advancing a synthetic MOTS-c-derived peptide, CB4211, into a first-in-human study; specific primate findings are not detailed in the public literature reviewed here and should be confirmed against the sponsor's regulatory filings before being cited as a specific figure |
The pattern across this table: every efficacy finding comes from mice, the one human metabolic data point is an endogenous circulating-level change tied to exercise rather than to administration of the peptide, and the only administered-peptide human data comes from the early-phase safety program discussed next.
What adverse events were reported in the first-in-human MOTS-c program?
The compound-specific human program for a MOTS-c-derived peptide is CB4211, developed as a synthetic analog rather than the native sequence, and studied in an early-phase trial in a population with metabolic dysfunction (including participants with obesity and markers of fatty liver disease). What was reported, in neutral terms, is summarized below. Because this is an early-phase program, the published and publicly disclosed adverse-event detail is narrower than a later-phase trial would produce, and the frequencies below should be treated as a summary rather than a full line listing.
- Administration-site findings. As with other subcutaneously administered peptides in early-phase study, administration-site reactions (localized redness or discomfort at the site) were among the events recorded; the program description does not indicate these were treatment-limiting.
- Gastrointestinal findings. Early-phase disclosures for this class of metabolic peptide commonly record mild gastrointestinal events (nausea, appetite change) during a dose-escalation design; the specific frequency reported for CB4211 should be confirmed against the primary trial record, since the public literature reviewed for this article does not carry a confirmed, citable frequency table for this program.
- Serious adverse events. No serious treatment-related adverse event tied to CB4211 is described in the materials available for this review. This should not be read as a confirmed null finding; it reflects the limits of what is publicly available in the indexed literature at the time of writing, and it is the single statement in this article a reader should verify directly against the sponsor's clinical trial registry entry before relying on it.
- Mouse and primate preclinical tolerability. The preclinical toxicology package that supported moving to a first-in-human study is, by design, the stage where a tolerated amount and exposure margin are established before any human dosing begins; the public literature reviewed here does not provide a specific organ-level finding for the primate arm, so that detail is flagged rather than stated as fact.
How does circulating MOTS-c relate to metabolic endpoints across the published studies?
The mouse data linking MOTS-c to fasting glucose and body composition sits alongside a separate, more indirect human observation: circulating MOTS-c rises after acute exercise. These are two different kinds of evidence. The mouse studies gave the peptide and measured a metabolic endpoint afterward. The human exercise study measured an endogenous change in a peptide that is already present in the body and did not administer anything. Readers researching MOTS-c should keep these two evidence types separate rather than treating the human correlation as confirmation of the mouse administration findings.
Age is a second variable that runs through this literature. The exercise study's mouse arm specifically examined aged animals rather than young adults, and the reported muscle-function improvement was framed against age-related physical decline rather than against a general fitness endpoint. That detail matters for anyone trying to map the mouse finding onto a different age group or a different starting health status, because the study was not designed to answer whether the same administration produces the same muscle-function change in young, metabolically healthy animals. The myostatin-signaling study has a similar scope limit: it used a defined muscle-wasting model, and its finding about myostatin pathway activity describes that wasting context specifically, not skeletal muscle generally.
Taken together, the published record supports a metabolic and mitochondrial-signaling role for MOTS-c that has been demonstrated across several independent mouse models and extended, carefully, into one human exercise correlation and one early-phase human safety program built around a synthetic analog. It does not yet support a claim that the mouse metabolic findings have been reproduced by direct administration of MOTS-c itself in humans.
How is MOTS-c research material handled in a lab setting?
Research-grade MOTS-c ships as a lyophilized powder and is reconstituted with a diluent before use, following the same general math used across the peptide catalog; the step-by-step calculation is covered in Reconstituting Lyophilized Peptides. Before using any lot, the certificate of analysis should be checked for identity and purity data, covered in How to Read a Peptide Certificate of Analysis. MOTS-c is grouped with other mitochondrial-pathway research compounds in Mitochondrial Research Compounds: NAD+, MOTS-c and SS-31 Compared. A research-grade vial is available at /products/mots-c for laboratory use.
Frequently asked questions
Is MOTS-c the same molecule studied in the first-in-human trial?
No. The first-in-human program used CB4211, a synthetic peptide derived from the MOTS-c sequence rather than the native 16-amino-acid peptide itself. The mouse and cell data cited above used the native sequence.
Which species have appeared in the published MOTS-c efficacy literature?
Mouse is the primary efficacy species across the foundational metabolic, nuclear-translocation and muscle-signaling studies. A non-rodent species, typically a primate, appears at the preclinical safety stage that supports moving into human study, consistent with standard development practice, though the public literature reviewed here does not detail primate-specific efficacy findings.
Does exercise increase the amount of MOTS-c a person is exposed to?
Published human data report a rise in circulating MOTS-c around an acute exercise session. This is an endogenous change, not evidence about administering the peptide, and should not be read as a dosing data point.
What metabolic endpoints have the mouse studies measured?
Fasting glucose, glucose tolerance, insulin sensitivity and body composition (the ratio of fat mass to lean mass) are the endpoints reported across the mouse literature cited here.
Were any serious adverse events reported in the CB4211 program?
The materials available for this review do not describe a serious treatment-related adverse event tied to CB4211. Given the early-phase, publicly limited nature of the disclosed data, this specific point should be checked against the sponsor's primary trial record before being treated as a settled fact.
Does MOTS-c work the same way as NAD+ or SS-31?
No. All three are studied in mitochondrial-pathway research, but through different mechanisms; the comparison across all three is covered in Mitochondrial Research Compounds: NAD+, MOTS-c and SS-31 Compared.
Why does the nuclear-translocation study matter for interpreting MOTS-c's mechanism?
That study showed the peptide is not confined to a single cellular compartment: under metabolic stress, it moves to the nucleus and regulates a distinct set of genes, which means its reported metabolic effects likely reflect more than one mechanism rather than a single receptor-binding event.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;22(3):443-453. PubMed 26256392.
- Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Mitochondrially derived peptides as novel regulators of metabolism. J Physiol. 2017;595(21):6613-6621. PubMed 28393420.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed 33452243.
- Kumagai H, Kim SJ, Miller B, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PubMed 33427053.
- Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exercise-induced skeletal muscle adaptation? J Physiol. 2015;593(23):5155-5157. PubMed 26534771.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524. PubMed 30017822.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



